JournalsHub
.online
Find My Journal
AH

Axel Hauschild

Christian-Albrechts-Universität zu Kiel DE

ORCID iD 0000-0002-1212-9587
811
Publications
72,777
Citations
110
H-Index
411
i10-Index
14.25
2yr Mean Cite
-
Cite/Paper
Data combined from OpenAlex . OA = OpenAlex S2 = Semantic Scholar
Verify on Google Scholar

Publication & Citation Trends

Most Cited Works

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation OA
Paul B. Chapman, Axel Hauschild, Caroline Robert, John B.A.G. Haanen, Paolo A. Ascierto +23 more
New England Journal of Medicine 2011
7,664
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma OA
Caroline Robert, L. Thomas, Igor Bondarenko, Steven O’Day, Jeffrey S. Weber +19 more
New England Journal of Medicine 2011
4,455
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild, Jean‐Jacques Grob, Lev Demidov, Thomas Jouary, Ralf Gutzmer +16 more
The Lancet 2012
2,956
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib OA
Caroline Robert, Bogusława Karaszewska, Jacob Schachter, Piotr Rutkowski, Andrzej Maćkiewicz +22 more
New England Journal of Medicine 2014
2,635
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma OA
Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas, E. Levchenko, Filippo de Braud +30 more
New England Journal of Medicine 2014
1,852

Publications

806 total

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma PDF

Caroline Robert, Jean‐Jacques Grob, Daniil Stroyakovskiy, Bogusława Karaszewska, Axel Hauschild et al. - New England Journal of Medicine, 2019
Cited by 1,350 OpenAlex

Melanoma

Dirk Schadendorf, Alexander C. J. van Akkooi, Carola Berking, Klaus Griewank, Ralf Gutzmer et al. - The Lancet, 2018
Cited by 1,446 OpenAlex

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma PDF

Michael R. Migden, Danny Rischin, Chrysalyne D. Schmults, Alexander Guminski, Axel Hauschild et al. - New England Journal of Medicine, 2018
Cited by 1,371 OpenAlex

Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma PDF

Georgina V. Long, Axel Hauschild, Mario Santinami, Victoria Atkinson, Mario Mandalà et al. - New England Journal of Medicine, 2017
Cited by 1,465 OpenAlex

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy PDF

Alexander M.M. Eggermont, Vanna Chiarion‐Sileni, Jean‐Jacques Grob, Reinhard Dummer, Jedd D. Wolchok et al. - New England Journal of Medicine, 2016
Cited by 1,308 OpenAlex

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas, E. Levchenko, Filippo de Braud et al. - The Lancet, 2015
Cited by 1,375 OpenAlex

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib PDF

Caroline Robert, Bogusława Karaszewska, Jacob Schachter, Piotr Rutkowski, Andrzej Maćkiewicz et al. - New England Journal of Medicine, 2014
Cited by 2,635 OpenAlex

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma PDF

Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas, E. Levchenko, Filippo de Braud et al. - New England Journal of Medicine, 2014
Cited by 1,852 OpenAlex

Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

Grant A. McArthur, Paul B. Chapman, Caroline Robert, James Larkin, John B.A.G. Haanen et al. - The Lancet Oncology, 2014
Cited by 976 OpenAlex

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

Axel Hauschild, Jean‐Jacques Grob, Lev Demidov, Thomas Jouary, Ralf Gutzmer et al. - The Lancet, 2012
Cited by 2,956 OpenAlex

Research Topics

Cutaneous Melanoma Detection and Management (371) Melanoma and MAPK Pathways (296) CAR-T cell therapy research (165) Nonmelanoma Skin Cancer Studies (155) Cancer Immunotherapy and Biomarkers (125)

Frequent Co-Authors

CA
Caroline Robert
10 joint publications
DI
Dirk Schadendorf
10 joint publications
CÉ
Célèste Lebbé
7 joint publications
VA
Vanna Chiarion‐Sileni
7 joint publications
CL
Claus Garbe
6 joint publications
AN
Antoni Ribas
6 joint publications

Affiliations

Goethe University Frankfurt
DE 2010 - 2003
European Organisation for Research and Treatment of Cancer
NL 2007 - 2007
The University of Sydney
AU 2012 - 2012
Deaconess Hospital
US 2010 - 2010
Beth Israel Deaconess Medical Center
US 2010 - 2010

External Profiles

OpenAlex Profile Search Semantic Scholar ORCID Profile Google Scholar

Share Profile

Back to Researchers
Comparison Shortlist
0 journals
Est. APC Budget: $0
Compare Now